Transforming Oncology Through
Science and AI Technology
Onco-Innovations pioneers cancer research, developing cutting-edge therapies to prevent and treat cancer. With exclusive global rights to groundbreaking technology targeting solid tumors, our aim is to set new targets in oncology, improving patient outcomes and offering hope.
Through the acquisition of Inka Health and its SynoGraph™ AI platform, we are enhancing precision oncology by accelerating patient identification, optimizing treatment planning, and streamlining drug development across our pipeline
ONC010ᵀᴹ
The Next-Generation Drug Formulation
Proprietary Formula
Aims to prevent DNA repair to eliminate cancer cells
Enhanced Delivery
Nanoparticles ensure precision targeting
Optimized Results
Designed to work with chemo/radiation/surgery to potentially improve outcomes and reduce side effects
10 Year Growth Projection
Market Value in Billions $(USD)
Global cancer cases are projected to rise by 47% by 2040²
CAGR of 8.9%³
Existing treatment gaps in precision medicine and early diagnostics
Addressable market: Colorectal cancer alone represents a $18 billion market
Unmet needs include faster diagnostics and cost-effective therapies